Retraction appears for faked study of Novartis anti-cancer compound

Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.
Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted.

In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed to fight brain tumors. Here’s the notice for the study in question, published in Cancer Research:
Continue reading Retraction appears for faked study of Novartis anti-cancer compound

Paper on circulating tumor cells taken out of circulation after lab error

medical oncologyA group of researchers at the Guangdong Academy of Medical Sciences in Guangzhou, China have retracted a paper that came out of a clinical trial on transarterial chemoembolization, a targeted kind of chemotherapy.

According to the notice, one of the authors mixed up the control samples with the clinical samples, and “could not recall which samples were in the wrong group.” The paper hasn’t yet been cited, according to Thomson Scientific’s Web of Knowledge.

Here’s the notice in Medical Oncology:

Continue reading Paper on circulating tumor cells taken out of circulation after lab error

Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

lancetrmLancet Respiratory Medicine has issued an expression of concern for a meta-analysis on tracheostomy in the intensive care unit that they published earlier this year.

The paper, “Effect of early versus late or no tracheostomy on mortality of critically ill patients receiving mechanical ventilation: a systematic review and meta-analysis“, came from a group at Harvard, Weill Cornell and the University of Athens. The authors purported to find that: Continue reading Lancet journal puts ICU paper on watch after authors acknowledge potentially fatal flaw

“Significant” copying forces retraction of sternotomy paper

icatsInteractive Cardiovascular and Thoracic Surgery has yanked a 2005 sternotomy paper by a group of researchers who plagiarized from an earlier article on the subject.

The article, “The complications of repeat median sternotomy in paediatrics: six-months follow-up of consecutive cases,” came from a team at Glenfield Hospital in Leicester, England, and has been cited eight times, according to Scopus.

Here’s the notice:

Continue reading “Significant” copying forces retraction of sternotomy paper

“Know how to recognize pseudoscience:” Reader reveals how fish oil paper came to be retracted

Ian Garber
Ian Garber

After our post yesterday on a fishy retraction from author Brian Peskin, a reader who alerted the journal to problems got in touch to give us the lowdown.

Ian Garber is in the last year of medical residency at the University of British Columbia. Here’s the story he told us via email: Continue reading “Know how to recognize pseudoscience:” Reader reveals how fish oil paper came to be retracted

“Undeclared competing interest” sinks fish oil takedown by author fined for deceptive claims

Snake swallowing a whole fish
Image via Jesse Palmer

The Journal of Lipids has retracted an aggressively negative review article called “Why Fish Oil Fails,” written by one Brian S. Peskin, whose bogus health claims have landed him in plenty of hot water in the past.

Here’s the notice: Continue reading “Undeclared competing interest” sinks fish oil takedown by author fined for deceptive claims

“I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

douglas_melton
Doug Melton

Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.

Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.

The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Continue reading “I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

Heart journal pulls paper for image manipulation

cardresCardiovascular Research has retracted a 2010 paper by a group of prominent cardiology researchers in Brazil.

The reason: Image manipulation — which the authors say didn’t materially affect the conclusions of the paper.

The article, “FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex,” came from a group led by Ana Paula Dalla Costa, from the State University of Campinas.

Here’s the abstract of the study, which has been cited 19 times, according to Thomson Scientific’s Web of Knowledge: Continue reading Heart journal pulls paper for image manipulation

What was behind an oddly-worded dental retraction? The authors stole someone’s thesis

Image via Tambako
Image via Tambako

A dentistry journal has retracted a paper after discovering the research was lifted from dissertation work by two people unrelated to the paper authors.

Here’s the notice for “Treatment of mandibular angle fracture with a 2 mm, 3-dimensional rectangular grid compression miniplates: A prospective clinical study“: Continue reading What was behind an oddly-worded dental retraction? The authors stole someone’s thesis

Boldt’s data were fake in 1996 paper

Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg
Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg

Update, 4 p.m. EST, 10/29/14: As a commenter points out, we didn’t quite get this one right. The Boldt paper that has been retracted was not previously retracted for lack of IRB approval. Rather, it was a heretofore unretracted article, from 1996, which German investigators have determined contained faked data. We’ve made edits below using strikethroughs, and have changed the headline to better reflect the content. We apologize for the errors.

We’ve commented before on the fact that we’ve noticed there’s often more to retractions whose stated reason is lack of institutional review board (IRB) approval. We can understand editors’ inclination to act as quickly as possible to issue a retraction, the scientific publishing equivalent of jailing Al Capone for tax evasion. But we appreciate it even more when said editors return to the scene of the crime, as it were, when new important details come out.

Case in point: Anesthesia & Analgesia has amended its retraction of a 2009 1996 study by Joachim Boldt — who with nearly 90 retractions once held the record in that department — based on findings that the data in that paper were fabricated.

The article was titled “Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy,” “The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patient.”  had previously been retracted because Boldt had failed to obtain adequate ethics approval for the research. But now comes this, According to the retraction notice from editor in chief Steven Shafer: Continue reading Boldt’s data were fake in 1996 paper